Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Trikafta in Cystic Fibrosis (F/MF)
NCT04545515Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jan 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of elexacaftor + tezacaftor + ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Jan 2021; status: completed.
02
Drugs
elexacaftor + tezacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT04545515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04545515.